• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.67% Nasdaq Up1.47%

    Opko Health, Inc. (OPK)

    -NYSE
    17.89 Up 0.16(0.90%) May 27, 4:03PM EDT
    |After Hours : 17.76 Down 0.13 (0.73%) May 27, 5:49PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Opko Health, Inc.
    4400 Biscayne Boulevard
    Miami, FL 33137
    United States - Map
    Phone: 305-575-4100
    Website: http://www.opko.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:674

    Business Summary 

    OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics. The company develops various solutions to diagnose, treat, and prevent various conditions, including point-of-care tests, molecular diagnostics tests, laboratory developed tests, and proprietary pharmaceuticals and vaccines. Its products include 4Kscore test that measures the blood plasma levels of four different prostate-derived kallikrein proteins. The company’s lead product candidates comprise Rayaldee to treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency; and Alpharen to treat hyperphosphatemia in stage 5 patients on chronic hemodialysis. It is also developing CTP, hGH-CTP for the treatment of growth hormone deficiency; Factor VII-CTP for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX; Inspiromatic, a powder inhaler for use in the therapy for asthma, chronic obstructive pulmonary disease, cystic fibrosis, and other respiratory diseases; and rolapitant for the prevention of chemotherapy induced nausea and vomiting, as well as focuses on the development of a long-acting oxyntomdulinGLP-1/glucagon dual receptor agonist. In addition, the company is developing Claros1 immunoassay instrument system that provides rapid blood test results and enables complex tests to be run in point-of-care settings; drugs for the treatment cancer, heart disease, metabolic disorders, and various genetic anomalies; and has various therapeutic agents in clinical development for the treatment of respiratory disorders. Further, it operates a full-service medical laboratory specializing in urologic pathology. OPKO Health, Inc. is based in Miami, Florida.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Opko Health, Inc.

    Corporate Governance 
    Opko Health, Inc.’s ISS Governance QuickScore as of May 1, 2015 is 9. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 2; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Phillip Frost M.D., Ph.D., 78
    Chairman and Chief Exec. Officer
    790.00K205.00K
    Dr. Jane H. Hsiao Ph.D., MBA., 68
    Vice Chairman and Chief Technical Officer
    560.00K1.22M
    Mr. Adam Logal , 37
    Chief Financial Officer, Chief Accounting Officer, Sr. VP and Treasurer
    310.00K0.00
    Mr. Steven D. Rubin J.D., 55
    Exec. VP of Admin. and Director
    490.00K2.00M
    Mr. Kate Inman Esq.,
    Deputy Gen. Counsel and Sec.
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders